Innate Pharma (IPHA) Non Operating Income (2020 - 2022)

Innate Pharma (IPHA) posted quarterly Non Operating Income of -$621323.0 for Q4 2022, up 74.22% on a QoQ basis from -$2.4 million in Q2 2022.

Innate Pharma (IPHA) Non Operating Income (2020 - 2022) Analysis & Trends

Innate Pharma (IPHA) has reported Non Operating Income for 2 consecutive years, with -$621323.0 the latest figure, recorded in Q4 2022.

Quarterly Non Operating Income changed N/A year-over-year to -$621323.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$7.5 million (changed N/A YoY) and the FY2025 annual result came in at $5.5 million, up 129.61% from the prior year.
Non Operating Income grew to -$621323.0 in Q4 2022 per IPHA's latest filing, from -$2.4 million in the prior quarter.
Over the last five years, Non Operating Income for IPHA reached as high as -$621323.0 in Q4 2022 and fell as low as -$2.4 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Op. Inc. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-9.22 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	188.30 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	5.75 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-8.59 Mn
10	Innate Pharma	157.68 Mn	157.68 Mn	-	-

Download Data